

F C Bidard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/446431/publications.pdf>

Version: 2024-02-01

133
papers

9,235
citations

38660

50
h-index

42291

92
g-index

139
all docs

139
docs citations

139
times ranked

11046
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
2	Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2008, 14, 7004-7010.	3.2	350
3	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. <i>Annals of Oncology</i> , 2014, 25, 1729-1735.	0.6	308
4	Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14524-14529.	3.3	296
5	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2583-2593.	3.2	289
6	Circulating tumor DNA as a noninvasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. <i>Molecular Oncology</i> , 2015, 9, 783-790.	2.1	248
7	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. <i>Annals of Oncology</i> , 2012, 23, 618-624.	0.6	239
8	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). <i>Annals of Oncology</i> , 2016, 27, 812-818.	0.6	234
9	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. <i>Annals of Oncology</i> , 2017, 28, 1996-2001.	0.6	223
10	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 179-188.	2.7	218
11	Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. <i>Annals of Oncology</i> , 2010, 21, 729-733.	0.6	216
12	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 560-567.	3.0	206
13	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
14	Circulating tumor cells: clinical validity and utility. <i>International Journal of Clinical Oncology</i> , 2017, 22, 421-430.	1.0	170
15	Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. <i>Annals of Oncology</i> , 2013, 24, 2057-2061.	0.6	166
16	Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. <i>International Journal of Cancer</i> , 2014, 134, 1207-1213.	2.3	161
17	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 375-384.	5.1	160
18	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 639-650.	12.5	152

#	ARTICLE	IF	CITATIONS
19	Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Clinical Chemistry</i> , 2017, 63, 691-699.	1.5	151
20	Circulating tumor cells in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 418-430.	2.1	150
21	Survival of breast cancer patients with meningeal carcinomatosis. <i>Annals of Oncology</i> , 2010, 21, 2183-2187.	0.6	144
22	Circulating tumor <scp>DNA</scp> and circulating tumor cells in metastatic triple negative breast cancer patients. <i>International Journal of Cancer</i> , 2015, 136, 2158-2165.	2.3	136
23	Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1765-1771.	0.6	133
24	Microfluidic: An innovative tool for efficient cell sorting. <i>Methods</i> , 2012, 57, 297-307.	1.9	133
25	Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse. <i>Clinical Cancer Research</i> , 2008, 14, 3306-3311.	3.2	128
26	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	3.2	119
27	A “class action” against the microenvironment: do cancer cells cooperate in metastasis?. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 5-10.	2.7	118
28	Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. <i>Annals of Oncology</i> , 2008, 19, 496-500.	0.6	110
29	Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. <i>Nature Communications</i> , 2018, 9, 1866.	5.8	102
30	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021, 15, 1647-1666.	2.1	101
31	Going with the Flow: From Circulating Tumor Cells to DNA. <i>Science Translational Medicine</i> , 2013, 5, 207ps14.	5.8	100
32	COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. <i>Breast Cancer Research</i> , 2020, 22, 55.	2.2	98
33	Efficacy of Circulating Tumor Cell Count “Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor “Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	3.4	92
34	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	3.2	91
35	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. <i>PLoS ONE</i> , 2013, 8, e67148.	1.1	82
36	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80

#	ARTICLE	IF	CITATIONS
37	Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 3934-3941.	3.2	78
38	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodiges-14 Trial. <i>Cells</i> , 2019, 8, 516.	1.8	78
39	Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. <i>Molecular Oncology</i> , 2016, 10, 481-493.	2.1	75
40	Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. <i>Breast Cancer Research</i> , 2012, 14, R29.	2.2	72
41	ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. <i>Oncogene</i> , 2020, 39, 487-502.	2.6	72
42	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5767-5771.	3.2	68
43	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2109-2115.	3.2	65
44	Circulating Tumor Cells in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz026.	1.4	63
45	High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection. <i>Lab on A Chip</i> , 2015, 15, 2090-2101.	3.1	62
46	Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. <i>Journal of Clinical Pathology</i> , 2008, 61, 570-576.	1.0	60
47	Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. <i>Annals of Oncology</i> , 2013, 24, 1231-1238.	0.6	59
48	Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data. <i>Clinical Cancer Research</i> , 2015, 21, 1298-1304.	3.2	56
49	Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study. <i>International Journal of Breast Cancer</i> , 2013, 2013, 1-5.	0.6	53
50	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017, 28, 103-109.	0.6	52
51	Establishment and Validation of Circulating Tumor Cell-Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2013, 19, 1596-1602.	3.2	49
52	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. <i>Molecular Oncology</i> , 2014, 8, 1588-1602.	2.1	49
53	Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial. <i>Cancer Letters</i> , 2015, 360, 213-218.	3.2	45
54	International study on inter-reader variability for circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R43.	2.2	43

#	ARTICLE	IF	CITATIONS
55	ESR1 mutations: a new biomarker in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 599-611.	1.5	43
56	Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. <i>Annals of Oncology</i> , 2013, 24, 2999-3004.	0.6	42
57	Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. <i>Clinical Chemistry</i> , 2018, 64, 317-328.	1.5	42
58	Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. <i>Breast Cancer Research</i> , 2019, 21, 121.	2.2	42
59	High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies. <i>Clinical Chemistry</i> , 2020, 66, 606-613.	1.5	42
60	A single droplet digital PCR for ESR1 activating mutations detection in plasma. <i>Oncogene</i> , 2020, 39, 2987-2995.	2.6	42
61	Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. <i>Annals of Oncology</i> , 2009, 20, 1836-1841.	0.6	40
62	Translating metastasis-related biomarkers to the clinic—progress and pitfalls. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 169-179.	12.5	40
63	Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2021, 23, 31.	2.2	39
64	Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?. <i>European Journal of Surgical Oncology</i> , 2017, 43, 949-962.	0.5	38
65	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014, 8, 150-158.	2.1	37
66	Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa090.	1.4	37
67	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	0.6	37
68	ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. <i>Bioinformatics</i> , 2020, 36, 3888-3889.	1.8	35
69	ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. <i>Oncotarget</i> , 2016, 7, 73337-73346.	0.8	34
70	Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging. <i>Seminars in Cancer Biology</i> , 2022, 86, 262-272.	4.3	34
71	Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. <i>Oncologist</i> , 2016, 21, 281-282f.	1.9	33
72	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020, 66, 1093-1101.	1.5	33

#	ARTICLE	IF	CITATIONS
73	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 115.	2.3	33
74	Disseminated and circulating tumor cells in gastrointestinal oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 103-115.	2.0	31
75	Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. <i>British Journal of Cancer</i> , 2021, 124, 1207-1213.	2.9	31
76	HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 86.	2.2	30
77	HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. <i>ESMO Open</i> , 2021, 6, 100154.	2.0	30
78	HPV circulating tumor DNA to monitor the efficacy of anti-HPV therapy in metastatic squamous cell carcinoma of the anal canal: A case report. <i>International Journal of Cancer</i> , 2017, 141, 1667-1670.	2.3	29
79	Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0144359.	1.1	27
80	FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool. <i>Lab on A Chip</i> , 2015, 15, 811-822.	3.1	26
81	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020, 20, 352.	1.1	24
82	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021, 154, 128-137.	1.3	24
83	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. <i>BMJ Open</i> , 2022, 12, e055821.	0.8	23
84	Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1622-1622.	0.8	22
85	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
86	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2198-2207.	2.9	21
87	Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. <i>Cancer Research</i> , 2014, 74, 2946-2961.	0.4	20
88	A three dimensional thermoplastic microfluidic chip for robust cell capture and high resolution imaging. <i>Biomicrofluidics</i> , 2014, 8, 024109.	1.2	20
89	Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. <i>Cancers</i> , 2019, 11, 396.	1.7	20
90	Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature. , 2019, 7, 317.		20

#	ARTICLE	IF	CITATIONS
91	Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. <i>British Journal of Cancer</i> , 2017, 116, 356-361.	2.9	19
92	RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. <i>European Journal of Cancer</i> , 2017, 83, 185-193.	1.3	19
93	Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. <i>Annals of Oncology</i> , 2015, 26, 1704-1709.	0.6	18
94	Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification. <i>PLoS ONE</i> , 2012, 7, e47390.	1.1	18
95	Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?. <i>Annals of Translational Medicine</i> , 2021, 9, 1113-1113.	0.7	17
96	Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 871-875.	1.7	16
97	Plasma thymidine kinase 1 activity and outcome of ER+ HER2+ metastatic breast cancer patients treated with palbociclib and endocrine therapy. <i>Breast Cancer Research</i> , 2020, 22, 98.	2.2	16
98	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15
99	Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics). <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1380-1392.	1.2	15
100	Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 389-396.	0.4	14
101	Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3560-3570.	3.3	14
102	Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. <i>Genome Medicine</i> , 2021, 13, 44.	3.6	13
103	Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. <i>Analytical Chemistry</i> , 2022, 94, 6297-6303.	3.2	13
104	Contemporary issues and the potential uses of capecitabine in metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 582-589.	3.4	11
105	Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1458-1459.	0.6	11
106	Circulating tumor cell count and thrombosis in metastatic breast cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1981-1988.	1.9	11
107	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
108	Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). <i>Angiogenesis</i> , 2020, 23, 193-202.	3.7	11

#	ARTICLE	IF	CITATIONS
109	Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 14.	2.3	10
110	Enhancer rewiring in tumors: an opportunity for therapeutic intervention. <i>Oncogene</i> , 2021, 40, 3475-3491.	2.6	10
111	Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma. <i>European Journal of Cancer</i> , 2009, 45, 1979-1986.	1.3	9
112	Trends in cancer-targeted antibody-drug conjugates. <i>Targeted Oncology</i> , 2014, 9, 1-8.	1.7	7
113	Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. <i>Cancer Research</i> , 2017, 77, S3-01-S3-01.	0.4	7
114	GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. <i>Communications Biology</i> , 2022, 5, 373.	2.0	7
115	T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , 2017, 12, e138-e139.	0.5	5
116	Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centre. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002946.	0.8	5
117	Abstract 3390: Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial. <i>Cancer Research</i> , 2020, 80, 3390-3390.	0.4	5
118	ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer. <i>Journal of Breast Cancer</i> , 2020, 23, 218.	0.8	5
119	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
120	Circulating tumor DNA detection in hepatocellular carcinoma. <i>Annals of Oncology</i> , 2018, 29, 1094-1096.	0.6	4
121	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. <i>Cancers</i> , 2021, 13, 140.	1.7	4
122	Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. <i>Breast Cancer Research</i> , 2021, 23, 9.	2.2	4
123	Circulating Tumor Cells, a Tremendous Prognostic Factor in Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv281.	3.0	3
124	Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	3
125	Impact of circulating tumor DNA early detection and serial monitoring in the management of stage I to III colorectal cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S315-S315.	0.7	3
126	Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression. <i>Modern Pathology</i> , 2022, 35, 1624-1635.	2.9	3

#	ARTICLE	IF	CITATIONS
127	Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial. <i>Annals of Oncology</i> , 2016, 27, vi150.	0.6	2
128	FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells. <i>Methods in Molecular Biology</i> , 2017, 1547, 211-220.	0.4	2
129	Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach. <i>Cancers</i> , 2022, 14, 1890.	1.7	2
130	Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals. <i>Cancers</i> , 2022, 14, 2114.	1.7	2
131	ERBB3-Activating Mutations in Small Bowel Adenocarcinomas. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	1
132	Immune-related toxicities in non-small cell lung cancer: Real-life predictors of outcome to checkpoint inhibitors?. <i>Journal of Clinical Oncology</i> , 2019, 37, e14135-e14135.	0.8	1
133	¹⁸ F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. <i>Diagnostics</i> , 2021, 11, 1353.	1.3	0